Our Platform

Expanding patients access to genetic medicines

Genetic medicines have resulted in remarkable results for patients. Yet, extreme product complexity and cost has severely limited patient access to existing genetic medicines.

kelonia’s technology will unlock the full promise of genetic medicine by overcoming the central challenge that is shared across all existing technologies: precise and efficient gene delivery directly into the patient.

This will enable improved patient outcomes and dramatically better reach and access than what is possible with the genetic medicines that exist today. At the same time, it can be applied to genetic medicines for a broad range of diseases.

iGPS® technology is built on a well-understood gene delivery system

kelonia's iGPS® technology is built on a lentiviral vector (LVV) engineered with a targeting molecule that uniquely defines the iGPS particle’s specificity and an optimized fusogen that enables efficient delivery of therapeutic transgenes.

Bringing gene therapies into common medical practice

kelonia’s iGPS is “off-the-shelf” and will reach patients where and when they are needed.

Enabling tissue-specific gene delivery via direct infusion

Efficient gene delivery permits low dose levels of iGPS particles and systemic administration, without the requirement for pretreatment chemotherapies.

The patient’s cells are engineered within the body to express the therapeutic protein

kelonia’s iGPS particle delivers its therapeutic transgenes to the intended cells for durable engineering after a single dose to treat a broad range of diseases.